佐剂重组带状疱疹疫苗在炎症性肠病成人中的成本效益
研究构建马尔可夫模型,模拟100万例18、30、40、50岁的克罗恩病(CD)和溃疡性结肠炎(UC)患者,比较接种佐剂重组带状疱疹疫苗(RZV)与不接种的成本效益。结果所有年龄队列的增量成本效果比(ICER)均低于每质量调整生命年(QALY)10万美元,结论为RZV对全部成人IBD患者具有成本效益。
要点
- CD≥30岁和UC≥40岁接种RZV更有效且费用更低(CD ICER 6183–24878美元,UC 9163–19655美元)。
- CD<30岁和UC<40岁接种费用更高但QALY增加,ICER仍低于10万美元/QALY。
- 年龄单因素敏感性分析示成本平衡点CD为21.8岁、UC为31.5岁,概率敏感性分析92%模拟支持接种。
核心结论
- 在本模型中,RZV接种对所有成人IBD患者均具有成本效益。
研究设计与样本
- 构建马尔可夫模型,比较RZV接种与不接种在CD和UC患者中的成本效益。
- 每个IBD组模拟100万例患者,年龄分别为18、30、40和50岁。
主要发现
- 总体接种对CD和UC均有成本效益,所有年龄队列ICER均低于10万美元/QALY。
- CD≥30岁接种更有效且费用更低,ICER为6183–24878美元/QALY。
- UC≥40岁接种更有效且费用更低,ICER为9163–19655美元/QALY。
- CD 18岁接种费用更高但QALY增加,ICER为2098美元/QALY。
- UC 18岁和30岁接种费用更高但QALY增加,ICER分别为11609和1343美元/QALY。
关键数值与推荐
- 年龄单因素敏感性分析示成本平衡点CD组为21.8岁、UC组为31.5岁。
- 概率敏感性分析中CD和UC模拟均有92%支持接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recombinant zoster vaccine (RZV) is recommended for all adults ≥19 years of age who are at increased risk for HZ, including patients with inflammatory bowel disease (IBD). METHODS: A Markov model was constructed to compare the RZV cost-effectiveness with no vaccination in patients with Crohn's Disease (CD) and ulcerative colitis (UC). A simulated cohort of 1 million patients was used for each IBD group at ages 18, 30, 40, and 50. The primary objective of this analysis was to compare RZV cost-effectiveness in patients with CD and UC, comparing vaccination to no vaccination. RESULTS: Overall, vaccination is cost-effective for both CD and UC, with the incremental cost-effectiveness ratio (ICERs) below $100,000/quality-adjusted life years (QALY) for all age cohorts. For patients with CD, 30 years of age and older, and those with UC 40 years and older, vaccination was both more effective and less expensive than the non-vaccinated strategy (CD ≥30: ICERs $6183-$24,878 and UC ≥40: ICERs $9163-$19,655). However, for CD patients under 30 (CD 18: ICER $2098) and UC patients under 40 (UC = 18: ICER $11,609, and UC = 30: $1343), costs were greater for vaccinated patients, but there was an increase in QALY. One-way sensitivity analysis of age indicates that cost break-even occurs at age 21.8 for the CD group and 31.5 for the UC group. In probabilistic sensitivity analysis, 92% of both CD and UC simulations indicated that vaccination was preferred. CONCLUSION: In our model, vaccination with RZV was cost-effective for all adult patients with IBD.
引用
- Caldera F, Spaulding AC, Borah B, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease. Aliment Pharmacol Ther. 2023. PMID: 36896952. doi:10.1111/apt.17454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。